Viz.ai vs Recursion Pharmaceuticals

No, Recursion Pharmaceuticals has a higher valuation ($2.2B) compared to Viz.ai ($1.2B).

Viz.ai raised $289M while Recursion Pharmaceuticals raised N/A.

Viz.ai has the higher Awaira Score of 66.

Viz.ai: Viz.ai is an artificial intelligence healthcare company founded in 2016 that develops clinical decision support software for medical imaging analysis. The company specializes in AI-powered diagnostic tools that assist radiologists and emergency physicians in identifying acute neurological and cardiovascular conditions from medical imaging scans. Viz.ai's core platform uses deep learning algorithms to detect conditions such as stroke, pulmonary embolism, and aortic dissection, prioritizing urgent cases and flagging them for immediate physician review. The company's primary products include stroke detection software and platforms for identifying other time-critical conditions in emergency departments. Viz.ai operates within the broader clinical AI segment, competing with companies developing similar diagnostic imaging solutions. The platform integrates into existing hospital workflows and imaging infrastructure, providing real-time alerts to clinicians. Viz.ai has achieved significant market validation, with its technology adopted across numerous healthcare systems in the United States. The company raised Series D funding at a $1.2 billion valuation, reflecting investor confidence in the clinical AI market. Total funding reached $289 million across multiple rounds. The company's growth trajectory demonstrates expanded adoption among major hospital networks and healthcare providers seeking to improve diagnostic speed and clinical outcomes for emergency conditions. Viz.ai focuses specifically on time-critical emergency conditions where AI-assisted early detection directly impacts patient outcomes and hospital operations.. Recursion Pharmaceuticals: Recursion Pharmaceuticals is a computational biology company founded in 2013 that uses artificial intelligence and high-throughput screening to accelerate drug discovery and development. The company's platform combines automated microscopy, machine learning, and large-scale biological data analysis to identify novel drug candidates and therapeutic targets across multiple disease areas. Recursion operates a proprietary laboratory automation system capable of conducting millions of experiments to map cellular and molecular responses to chemical compounds. The company has developed computational models to predict drug efficacy and safety profiles before traditional clinical testing, significantly reducing development timelines and costs. As a publicly traded company with a $2.2 billion valuation, Recursion has built partnerships with major pharmaceutical firms including Bayer and Exscientia to validate its platform's effectiveness. The company's approach focuses on rare genetic diseases and oncology, leveraging its ability to process vast biological datasets that would be impractical through conventional methods. Recursion's competitive advantage lies in its integration of wet laboratory automation with advanced machine learning analytics, enabling systematic drug discovery at scale. The company continues to expand its internal pipeline while licensing its technology to established pharma players, positioning itself as both a drug developer and a computational biology platform provider in the AI healthcare sector. Recursion combines automated laboratory systems with machine learning to systematize drug discovery at unprecedented scale and speed..

Recursion Pharmaceuticals was founded first in 2013. Viz.ai was founded in 2016.